Evidence map›Paper›PMID 26935231›Full record

ArticleClinical genitourinary cancer2016

Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer.

Tanya B Dorff, Anne K Schuckman, Rachel Schwartz, Sadaf Rashad, Ajaz Bulbul, Jie Cai, Jacek Pinski, Yanling Ma, Kathleen Danenberg, Eila Skinner and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical genitourinary cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Non-Coding RNA in Penile Cancer.Frontiers in oncology · 2022
    Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Tanya B DorffUSC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address: dorff@usc.edu.
Anne K SchuckmanUSC Keck School of Medicine, Institute of Urology, Los Angeles, CA.
Rachel SchwartzUSC Keck School of Medicine, Los Angeles, CA.
Sadaf RashadAll Saints University of Medicine, Chicago, IL.
Ajaz BulbulUSC Keck School of Medicine, Los Angeles, CA.
Jie CaiUSC Keck School of Medicine, Institute of Urology, Los Angeles, CA.
Jacek PinskiUSC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA.
Yanling MaUSC Keck School of Medicine, Department of Pathology, Los Angeles, CA.
Kathleen DanenbergResponse Genetics, Los Angeles, CA.
Eila SkinnerUSC Keck School of Medicine, Institute of Urology, Los Angeles, CA.
David I QuinnUSC Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, CA.
Keck Hospital of USC · USUSC Norris Comprehensive Cancer Center · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

objectiveTo describe the expression of tissue epidermal growth factor receptor (EGFR), excision-repair cross-complementation group 1 protein (ERCC1), and thymidylate synthase (TS) in patients with penile cancer and explore their association with stage and outcome.

methodsA total of 52 patients with penile squamous cell cancer who were treated at the University of Southern California from 1995 to 2010 were identified. Paraffin-embedded tissue underwent mRNA quantitation and immunohistochemistry for expression of EGFR, ERCC1, and TS. KRAS mutations were evaluated using polymerase chain reaction-based sequencing.

resultsEGFR overexpression was common by mRNA (median, 5.09; range, 1.92-104.5) and immunohistochemistry. EGFR expression > 7 was associated with advanced stage and poor differentiation (P = .01 and .034 respectively) but not with survival in multivariate analysis. ERCC1 mRNA expression was a median of 0.65 (range, 0.21-1.87). TS expression was a median of 1.88 (range, 0.54-6.47). ERCC1 and TS expression were not associated with grade, stage, or survival. There were no KRAS mutations identified. A total of 17 men received chemotherapy; 8 (47%) had an objective response, including 1 with a pathologic complete response. There was a trend for lower expression of EGFR corresponding to a higher likelihood of response (response rate [RR]) to chemotherapy: 67% RR in EGFR mRNA < 7 versus 33% RR in EGFR > 7 (P = .31).

conclusionsHigh expression of EGFR mRNA in squamous cell carcinoma of the penis is associated with advanced stage and poor differentiation, but not survival. In our small heterogeneous subset, molecular marker expression did not show a correlation with the likelihood of chemotherapy response. A prospective evaluation of the role of the EGFR pathway and its regulatory environment in penile cancer is warranted. Given the rarity of this cancer, collaborative prospective cohort evaluations and trials need to be encouraged.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Squamous CellDNA-Binding ProteinsEndonucleasesErbB ReceptorsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationNeoplasm StagingPenile NeoplasmsPrognosisDNA-Binding ProteinsEGFR protein, humanEndonucleasesErbB ReceptorsERCC1 protein, humanKRAS protein, humanProto-Oncogene Proteins p21(ras)Thymidylate SynthaseChemotherapy responseDNA repairGrowth factor receptorSquamous cell carcinomaTargeted therapy

Identifiers

PMID26935231
PMCPMC7515776
OpenAlexW2294153154

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.